Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis
A legfontosabb adatok
- Ki végzi
- Assistance Publique - Hôpitaux de Paris
- Hol
- Franciaország23 helyszín, 1 országbanVálassz országot a helyszínekhez
- Állapot
- Fut, nem toboroz
- Fázis
- 4. fázis
- Résztvevők
- 600 fő, tervezett
- Kezdés
- 2023. nov. 13.
- Várható befejezés
- 2027. márc. 4.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoport
- A vizsgált kezelések
- continuous pivotal βL-AB
- intermittent pivotal βL-AB
- AG infusion most 1 dose
- AG infusion for 5 days
- A regiszteradat frissítve
- 2026. október 16.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Adults (≥ 18 years)
- Hospital-acquired sepsis (according to sepsis 3.0 definitions) :; Patient hospitalized for more than 48 hours OR Patient discharged less than 48 hours ago; AND sepsis diagnosed within the last 24 hours
- One of the following risk factors for gram negative multidrug resistant pathogens:; Prior intravenous antibiotic use within 7 days prior to sepsis onset with the exception of antibiotic effective only against Gram-positive bacteria, penicillin A and macrolides; Prolonged hospital stay (≥ 15 days of hospitalization) within 3 months prior to sepsis onset Prolonged mechanical ventilation (≥ 5 days on mechanical ventilation) within 3 months prior to sepsis onset; Patients with indwelling devices (dialysis access lines, intravascular lines, urinary catheter, endotracheal or tracheostomy tube, gastrostomy or jejunostomy feeding tube); Patients known to be infected, colonized or carriers of MDR gram negative bacteria within 3 months prior to sepsis onset; Exposure to an antibiotic (amoxicillin-clavulanic acid, C2G, C3G, fluoroquinolones) within 3 months prior to sepsis onset; A trip abroad to known geographical areas at risk (in particular the Indian subcontinent, South-East Asia, the Middle East and North Africa, the Mediterranean Basin) within 3 months prior to sepsis onset; A functional or organic abnormality of the urinary tract in case of urinary tract infection
- Appropriate bacteriological sampling performed before starting antimicrobial therapy
- Expected stay in ICU of more than 3 days
Ki nem vehet részt
- Bone marrow transplant or chemotherapy-induced neutropenia
- Enrolment to another interventional drug study
- Known hypersensitivity to ceftazidime, piperacillin-tazobactam, cefepime, meropenem, ceftazidime-avibactam, ceftazolane-avibactam or to any of the excipients included in the corresponding pharmaceutical drugs,
- Known hypersensitivity to any cephalosporin antibacterial agent,
- Severe known hypersensitivity (eg, anaphylactic reaction, severe skin reaction) to any other beta-lactam antibiotic (eg, penicillins or monobactam ) or to any of its excipients
- Known contraindication to the aminoglycoside family including; Hypersensitivity to the active substance, to any aminoglycoside antibacterial agent or to any of the excipients included in the corresponding pharmaceutical drugs,; Cirrhosis of grades B and C according to the Child-Pugh classification; Myasthenia gravis; Simultaneous administration of another aminoglycoside; Association with ataluren
- Non-complicated urinary tract infection (corresponding to a positive ECBU not responsible for sepsis)
- Infections for which long-term antibiotic treatment > 8 days is strongly recommended (i.e., infective endocarditis, osteoarticular infections, anterior mediastinitis after cardiac surgery, hepatic or cerebral abscesses, chronic prostatitis for instance
- A priori known resistance to all the proposed beta-lactams or to amikacin
- Need for extrarenal treatment at inclusion according to the criteria of Gaudry et al
- Know hypersentitivity to any penem antibacterial agent,
- Presence of antibiotic therapyfor the new sepsis before randomisation: (> 2 doses of antibiotics or > 16h for continuous infusion
- Limitation of life support (comfort care applied only) at the time of screening
- Pregnancy or breastfeeding
- Subject deprived of freedom, subject under a legal protective measure
- Non affiliation to any health insurance system
- Refusal to participate to the study (patient or legal representative or family member or close relative if present)
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Patients hospitalized in ICU with sepsis (infection with life-threatening organ dysfunction according to sepsis 3.0 definitions) or septic shock presumably due to MDR-GNB (multidrug resistant Gram-negative bacteria). The study will be a prospective multicentre, randomized, open-label comparative continuous vs. intermittent pivotal βL (Beta Lactamine) antibiotic infusion strategies and combination vs. monotherapy trial conducted with a 2X2 factorial design.
A vizsgálat 4 csoportja
- continuous infusion dosing of a pivotal AND AG infusion for 5 daysA vizsgált kezelés
continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT group)
Kezelés: continuous pivotal βL-AB és AG infusion for 5 days
- intermittent infusion dosing of a pivotal βL-AB ND AG infusion for 5 daysA vizsgált kezelés
intermittent infusion dosing of a pivotal βL-AB (IID = control group) AND AG infusion for 5 days (long duration) as appropriate combination therapy (ACT = group)
Kezelés: intermittent pivotal βL-AB és AG infusion for 5 days
- continuous infusion dosing of a pivotal βL-AB AND AG infusion at most 1 doseA vizsgált kezelés
continuous infusion dosing of a pivotal βL-AB (CID group) AND AG infusion at most 1 dose (AMT group )
Kezelés: continuous pivotal βL-AB és AG infusion most 1 dose
- intermittent infusion dosing of a pivotal βL-AB AND AG infusion at most 1 doseA vizsgált kezelés
intermittent infusion dosing of a pivotal βL-AB (IID = group) AND AG infusion at most 1 dose (AMT group)
Kezelés: intermittent pivotal βL-AB és AG infusion most 1 dose
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- A regiszteradat frissítve
- 2026. október 16.